)
Biopharmaceutical company, Suven Life Sciences Limited, has secured one product patent each from Eurasia, Japan and Mexico corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The patents are valid through 2029.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s, Parkinson’s and Schizophrenia.
With these patents, Suven has a total of 13 patents from Eurasia, 12 from Japan and 17 from Mexico. These patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Venkat Jasti, CEO of Suven, stated in a release.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents. They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s, Parkinson’s and Schizophrenia.
With these patents, Suven has a total of 13 patents from Eurasia, 12 from Japan and 17 from Mexico. These patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Venkat Jasti, CEO of Suven, stated in a release.
